$0.29
9.34% yesterday
Nasdaq, Nov 25, 10:06 pm CET
ISIN
US38000Q1022
Symbol
GLYC
Sector
Industry

GlycoMimetics, Inc. Stock price

$0.29
+0.11 66.01% 1M
+0.02 6.37% 6M
-2.07 87.83% YTD
-1.22 80.98% 1Y
-1.52 84.13% 3Y
-5.23 94.80% 5Y
-8.86 96.86% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.03 9.34%
ISIN
US38000Q1022
Symbol
GLYC
Sector
Industry

Key metrics

Market capitalization $18.52m
Enterprise Value $4.39m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 439.00
P/S ratio (TTM) P/S ratio 1,852.00
P/B ratio (TTM) P/B ratio 1.63
Revenue (TTM) Revenue $10.00k
EBIT (operating result TTM) EBIT $-36.78m
Free Cash Flow (TTM) Free Cash Flow $-35.02m
Cash position $14.39m
EPS (TTM) EPS $-0.62
P/E forward negative
Short interest 12.61%
Show more

Is GlycoMimetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

GlycoMimetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast GlycoMimetics, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast GlycoMimetics, Inc.:

Hold
100%

Financial data from GlycoMimetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.01 0.01
-
100%
- Direct Costs 0.06 0.06
94% 94%
600%
-0.05 -0.05
95% 95%
-500%
- Selling and Administrative Expenses 17 17
1% 1%
173,600%
- Research and Development Expense 19 19
7% 7%
193,200%
-37 -37
6% 6%
-367,300%
- Depreciation and Amortization 0.06 0.06
94% 94%
600%
EBIT (Operating Income) EBIT -37 -37
9% 9%
-367,849%
Net Profit -40 -40
4% 4%
-397,400%

In millions USD.

Don't miss a Thing! We will send you all news about GlycoMimetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

GlycoMimetics, Inc. Stock News

Neutral
PRNewsWire
14 days ago
Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass. , Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced man...
Neutral
Business Wire
20 days ago
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, on December 7-10, 2024. ASH Annual Meeting abstracts...
Neutral
Business Wire
26 days ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics, Inc. (NasdaqGM: GLYC) and Crescent Biopharma, Inc. Pursuant to the terms of the agreement, shareholders of GlycoMimetics will own approximately 3.1% of the combined company. KSF is seeking to dete...
More GlycoMimetics, Inc. News

Company Profile

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Head office United States
CEO Harout Semerjian
Employees 35
Founded 2003
Website www.glycomimetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today